Angiogenesis and chronic inflammation: cause or consequence?

[1]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[2]  R. Medzhitov,et al.  Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines. , 2007, Current opinion in immunology.

[3]  Jian-xing Ma,et al.  Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy , 2007, Progress in Retinal and Eye Research.

[4]  R. Soares,et al.  Inhibition of S1P by polyphenols prevents inflammation and angiogenesis: NFkappaB, a downstream effector? , 2007, Free radical biology & medicine.

[5]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[6]  H. Augustin,et al.  Angiopoietins: a link between angiogenesis and inflammation. , 2006, Trends in immunology.

[7]  Jane Worthington,et al.  The CX3CL1–CX3CR1 system and psoriasis , 2006, Experimental dermatology.

[8]  A. Leonardi,et al.  NF-κB in solid tumors , 2006 .

[9]  W. B. van den Berg,et al.  Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis , 2006, Annals of the rheumatic diseases.

[10]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[11]  E. Berardesca,et al.  Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α , 2006, Journal of autoimmune diseases.

[12]  M. Shibuya,et al.  Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. , 2006, Blood.

[13]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[14]  L. Dworkin,et al.  Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  F. Mach,et al.  Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. , 2006, Atherosclerosis.

[16]  M. Lingen,et al.  Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. , 2006, The journal of investigative dermatology. Symposium proceedings.

[17]  M. Scott,et al.  TWEAK Is a Novel Arthritogenic Mediator , 2006, The Journal of Immunology.

[18]  T. Littlewood,et al.  Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis , 2006, Nature Medicine.

[19]  D. Noonan,et al.  Cytokines and chemokines as regulators of angiogenesis in health and disease. , 2006, Current pharmaceutical design.

[20]  U. Mrowietz,et al.  Leukocyte adhesion: a suitable target for anti-inflammatory drugs. , 2006, Current pharmaceutical design.

[21]  N. Nam.  Naturally occurring NF-kappaB inhibitors. , 2006, Mini reviews in medicinal chemistry.

[22]  J. Smolen,et al.  Interleukin-6: a new therapeutic target , 2006, Arthritis research & therapy.

[23]  R. Gay,et al.  Molecular and cellular basis of rheumatoid joint destruction. , 2006, Immunology letters.

[24]  D. P. Wubben,et al.  Metabolic syndrome: what's in a name? , 2006, WMJ : official publication of the State Medical Society of Wisconsin.

[25]  S. Flis,et al.  Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. , 2006, Anticancer research.

[26]  J. Bainbridge,et al.  Angiogenesis as a therapeutic target in arthritis: lessons from oncology. , 2006, Current pharmaceutical design.

[27]  A. Gasbarrini,et al.  Biological therapies for inflammatory bowel disease: research drives clinics. , 2006, Mini reviews in medicinal chemistry.

[28]  D. Steed.  Clinical Evaluation of Recombinant Human Platelet-Derived Growth Factor for the Treatment of Lower Extremity Ulcers , 2006, Plastic and reconstructive surgery.

[29]  A. Yoshimura,et al.  Signal transduction of inflammatory cytokines and tumor development , 2006, Cancer science.

[30]  C. Calhau,et al.  Adipocyte Size and Liability to Cell Death , 2006, Obesity surgery.

[31]  C. A. de la Motte,et al.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. , 2006, Gastroenterology.

[32]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[33]  Y. Konttinen,et al.  Oral treatment options for degenerative joint disease--presence and future. , 2006, Advanced drug delivery reviews.

[34]  R. Soares,et al.  Apigenin: is it a pro- or anti-inflammatory agent? , 2006, The American journal of pathology.

[35]  Jack Satsangi,et al.  New genes in inflammatory bowel disease: lessons for complex diseases? , 2006, The Lancet.

[36]  A. Facchini,et al.  Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. , 2006, Osteoarthritis and cartilage.

[37]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[38]  D. Jue,et al.  Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. , 2006, Immunology letters.

[39]  J. Saseen,et al.  When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis? , 2006, The Journal of family practice.

[40]  M. Schwartz,et al.  Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. , 2006, Current topics in medicinal chemistry.

[41]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[42]  H. Augustin,et al.  Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation , 2006, Nature Medicine.

[43]  J. H. Lee,et al.  IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes , 2006, Clinical Rheumatology.

[44]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[46]  N. Shear,et al.  Efalizumab, a reversible T-cell modulator for psoriasis , 2005, Journal of cutaneous medicine and surgery.

[47]  Shupei Wang,et al.  Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans Published, JLR Papers in Press, September 8, 2005. DOI 10.1194/jlr.M500294-JLR200 , 2005, Journal of Lipid Research.

[48]  I. McInnes,et al.  Cytokine networks—towards new therapies for rheumatoid arthritis , 2005, Nature Clinical Practice Rheumatology.

[49]  Yong Chul Lee.  The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy. , 2005, Current opinion in investigational drugs.

[50]  R. Vettor,et al.  Review article: adipocytokines and insulin resistance , 2005, Alimentary pharmacology & therapeutics.

[51]  R. Okamoto,et al.  Cellular and Molecular Mechanisms of the Epithelial Repair in IBD , 2005, Digestive Diseases and Sciences.

[52]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[53]  S. Ghosh,et al.  Interfering with interferons in inflammatory bowel disease , 2005, Gut.

[54]  M. Simons.  Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? , 2005, Journal of the American College of Cardiology.

[55]  J. Harlan,et al.  The role of endothelial cell apoptosis in inflammatory and immune diseases , 2005, Journal of thrombosis and haemostasis : JTH.

[56]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[57]  K. Asadullah,et al.  Cytokines as potential therapeutic targets for inflammatory skin diseases. , 2005, European cytokine network.

[58]  E. Ng,et al.  Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[59]  J. Zwerina,et al.  Pro-inflammatory cytokines in rheumatoid arthritis , 2005, Clinical reviews in allergy & immunology.

[60]  S. Kunkel,et al.  Neutrophil-derived cytokines: potential therapeutic targets in inflammation. , 2005, Current drug targets. Inflammation and allergy.

[61]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[62]  C. Weber.  Platelets and chemokines in atherosclerosis: partners in crime. , 2005, Circulation research.

[63]  Ralf J Ludwig,et al.  Lymphocyte trafficking to inflamed skin – molecular mechanisms and implications for therapeutic target molecules , 2005, Expert opinion on therapeutic targets.

[64]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[65]  C. Lines,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[66]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[67]  D. Binion,et al.  The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. , 2005, Inflammatory bowel diseases.

[68]  P. Sfikakis,et al.  Regression of neovascular age-related macular degeneration following infliximab therapy. , 2005, American journal of ophthalmology.

[69]  B. Bresnihan,et al.  Synovial tissue inflammation in early and late osteoarthritis , 2005, Annals of the rheumatic diseases.

[70]  J. Harlan,et al.  Targeting leukocyte integrins in human diseases , 2005, Journal of leukocyte biology.

[71]  P. Tak,et al.  Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. , 2005, Current pharmaceutical design.

[72]  F. Carraro,et al.  Role of inflammatory mediators in angiogenesis. , 2005, Current drug targets. Inflammation and allergy.

[73]  P. Tak,et al.  The role of chemokines in rheumatoid arthritis and osteoarthritis , 2005, Scandinavian journal of rheumatology.

[74]  H. Kaplan,et al.  Role of Complement and Complement Membrane Attack Complex in Laser-Induced Choroidal Neovascularization1 , 2005, The Journal of Immunology.

[75]  M. Detmar,et al.  Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. , 2004, The American journal of pathology.

[76]  H. Schreiber,et al.  Inflammation as a tumor promoter in cancer induction. , 2004, Seminars in cancer biology.

[77]  I. Charo,et al.  Chemokines in the pathogenesis of vascular disease. , 2004, Circulation research.

[78]  W. Markiewicz,et al.  Association Between Elevated Liver Enzymes and C-Reactive Protein: Possible Hepatic Contribution to Systemic Inflammation in the Metabolic Syndrome , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[79]  Hans Clevers,et al.  At the Crossroads of Inflammation and Cancer , 2004, Cell.

[80]  I. S. Wood,et al.  Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.

[81]  M. Dubinsky.  Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  J. Russo,et al.  Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. , 2004, Molecular endocrinology.

[83]  D. Rose,et al.  Obesity, adipocytokines, and insulin resistance in breast cancer , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[84]  G. Girolomoni,et al.  Chemokine networks in inflammatory skin diseases. , 2004, European journal of dermatology : EJD.

[85]  F. Schmitt,et al.  Angiogenesis: now and then , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[86]  L. Moreland.  Biologic Therapies on the Horizon for Rheumatoid Arthritis , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[87]  Wadih Arap,et al.  Reversal of obesity by targeted ablation of adipose tissue , 2004, Nature Medicine.

[88]  D. Wakefield,et al.  Expression of toll-like receptor 4 and its associated lipopolysaccharide receptor complex by resident antigen-presenting cells in the human uvea. , 2004, Investigative ophthalmology & visual science.

[89]  N. Funel,et al.  Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.

[90]  Tom Chang,et al.  longitudinal changes in self–reported visual functioningin AMD patients In a randomized controlled Phase I/II trial of lucentisTM (ranizumab; rHuFAB v2) , 2004 .

[91]  M. Feldmann,et al.  T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. , 2004, Current drug targets. Inflammation and allergy.

[92]  K. Brune.  Safety of anti-inflammatory treatment--new ways of thinking. , 2004, Rheumatology.

[93]  P. Giral,et al.  Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives , 2004, Clinical chemistry and laboratory medicine.

[94]  J. Pelletier,et al.  Cyclooxygenase-2 and prostaglandins in articular tissues. , 2003, Seminars in arthritis and rheumatism.

[95]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[96]  J. Hugot,et al.  Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. , 2003, Trends in immunology.

[97]  T. Ohnishi,et al.  Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. , 2003, Archives of oral biology.

[98]  M. Feldmann,et al.  Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis , 2003, Gene Therapy.

[99]  R. Jain,et al.  Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis , 2003, Circulation research.

[100]  A. Koch,et al.  Angiogenesis as a target in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[101]  Joan W. Miller,et al.  VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.

[102]  D. Walsh,et al.  Inflammation and angiogenesis in osteoarthritis. , 2003, Arthritis and rheumatism.

[103]  J. Ambati,et al.  Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[104]  D. Binion,et al.  Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. , 2003, Gastroenterology.

[105]  G. Yancopoulos,et al.  Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. , 2003, Blood.

[106]  A. Koch,et al.  The role of COX-2 in angiogenesis and rheumatoid arthritis. , 2003, Experimental and molecular pathology.

[107]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[108]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[109]  K. Hagihara,et al.  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[110]  E. Maltezos,et al.  Vascular endothelial growth factor in inflammatory bowel disease , 2003, International Journal of Colorectal Disease.

[111]  A. Weaver.  Differentiating the new rheumatoid arthritis biologic therapies. , 2003, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[112]  P. Tak,et al.  Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints , 2003, Annals of the rheumatic diseases.

[113]  H. Nagawa,et al.  Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease , 2003, Journal of gastroenterology.

[114]  J. Russo,et al.  Role of the Estrogen Antagonist ICI 182,780 in Vessel Assembly and Apoptosis of Endothelial Cells , 2003, Ultrastructural pathology.

[115]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[116]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[117]  C. Nathan.  Points of control in inflammation , 2002, Nature.

[118]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[119]  J. Smith,et al.  Phenotypic characterization of inflammatory cells from osteoarthritic synovium and synovial fluids. , 2002, Clinical immunology.

[120]  A. Luttun,et al.  Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1) , 2002 .

[121]  P. Winlove,et al.  VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. , 2002, Clinical and experimental rheumatology.

[122]  H. Nielsen,et al.  Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis , 2002, Inflammation Research.

[123]  R. Wilder,et al.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.

[124]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[125]  B. Lowell,et al.  Adipose tissue mass can be regulated through the vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[126]  Kazuhiro Usui,et al.  Proinflammatory Cytokine IL-1β Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction1 , 2002, The Journal of Immunology.

[127]  J. Reis-Filho,et al.  Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. , 2002, Journal of clinical pathology.

[128]  E. Paleolog.  Angiogenesis in rheumatoid arthritis , 2002, Arthritis research.

[129]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[130]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[131]  A. Colombo,et al.  Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. , 2002, The Journal of rheumatology.

[132]  J. Pelletier,et al.  Metalloproteases and inhibitors in arthritic diseases. , 2001, Best practice & research. Clinical rheumatology.

[133]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[134]  Y. Tagawa,et al.  Monocyte Chemotactic Protein-1 in the Vitreous of Patients with Proliferative Diabetic Retinopathy , 2001, Ophthalmologica.

[135]  V. Dahlmans,et al.  Protection From Obesity in Mice Lacking the VLDL Receptor , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[136]  F. Pallone,et al.  Mechanisms of tissue damage in inflammatory bowel disease , 2001, Current opinion in gastroenterology.

[137]  S. S. Lee,et al.  Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. , 2001, Clinical and experimental rheumatology.

[138]  A. Harris,et al.  The angiogenic pathway ‘vascular endothelial growth factor/flk‐1(KDR)‐receptor’ in rheumatoid arthritis and osteoarthritis , 2001, The Journal of pathology.

[139]  J. Redondo,et al.  Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a , 2001, The Journal of experimental medicine.

[140]  R. Danis,et al.  Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. , 2001, Archives of ophthalmology.

[141]  H. Shimano,et al.  Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. , 2001, Biochemical and biophysical research communications.

[142]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[143]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[144]  T. Dassopoulos,et al.  Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature , 2001, Annals of medicine.

[145]  M. Detmar.  The role of VEGF and thrombospondins in skin angiogenesis. , 2000, Journal of dermatological science.

[146]  A. Koch.  The role of angiogenesis in rheumatoid arthritis: recent developments , 2000, Annals of the rheumatic diseases.

[147]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[148]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[149]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[150]  M. Pla,et al.  Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[151]  R. Willette,et al.  Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor) , 2000 .

[152]  R. Maciewicz,et al.  Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis , 2000, Laboratory Investigation.

[153]  Y. Okada,et al.  Expression of vascular endothelial growth factor isoforms and their receptors Flt‐1, KDR, and neuropilin‐1 in synovial tissues of rheumatoid arthritis , 2000, The Journal of pathology.

[154]  J. Waltenberger,et al.  Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. , 2000, Circulation.

[155]  S. Schwartz,et al.  Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells , 2000, Nature Medicine.

[156]  M. Adachi,et al.  Vascular Endothelial Growth Factor Expression and Regulation of Murine Collagen-Induced Arthritis1 , 2000, The Journal of Immunology.

[157]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[158]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[159]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[160]  H. Oh,et al.  Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. , 1999, Investigative ophthalmology & visual science.

[161]  A. Levine,et al.  References Subscriptions Permissions Email Alerts Resistance of Crohn's Disease T Cells to Multiple Apoptotic Signals Is Associated with a Bcl-2/Bax Mucosal Imbalance , 2013 .

[162]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[163]  L. Raisz.  Prostaglandins and bone: physiology and pathophysiology. , 1999, Osteoarthritis and cartilage.

[164]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[165]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[166]  D. A. Wolf,et al.  Gene expression in space , 1999, Nature Medicine.

[167]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[168]  W. Langhans,et al.  New approaches in the pharmacological treatment of obesity , 1999, European journal of nutrition.

[169]  D. Walsh,et al.  Angiogenesis and arthritis. , 1999, Rheumatology.

[170]  E. Vignon,et al.  Increased serum C-reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. , 1998, Revue du rhumatisme.

[171]  B. Keyt,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[172]  G. Majno.  Chronic inflammation: links with angiogenesis and wound healing. , 1998, The American journal of pathology.

[173]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[174]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[175]  V. Dixit,et al.  Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[176]  E. Brahn,et al.  The effect of thalidomide and 2 analogs on collagen induced arthritis. , 1998, The Journal of rheumatology.

[177]  C. Moskaluk,et al.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. , 1998, Journal of immunology.

[178]  W. Hunter,et al.  Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization. , 1998, Clinical immunology and immunopathology.

[179]  I. Zachary,et al.  Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.

[180]  M. Hochberg,et al.  Osteoarthritis of the knee. , 2014, BMJ clinical evidence.

[181]  A. Kasza,et al.  Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein. , 1997, European journal of biochemistry.

[182]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[183]  J. Jackson,et al.  Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. , 1997, The Journal of rheumatology.

[184]  T. Spector,et al.  Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. , 1997, Arthritis and rheumatism.

[185]  I. Mikhailenko,et al.  Cellular Internalization and Degradation of Thrombospondin-1 Is Mediated by the Amino-terminal Heparin Binding Domain (HBD) , 1997, The Journal of Biological Chemistry.

[186]  M. Smith,et al.  Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. , 1997, The Journal of rheumatology.

[187]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[188]  E. Sigal,et al.  Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. , 1996, British journal of rheumatology.

[189]  R. O. Poyton,et al.  Oxygen sensing and molecular adaptation to hypoxia. , 1996, Physiological reviews.

[190]  D. Creamer,et al.  Altered vascular endothelium integrin expression in psoriasis. , 1995, The American journal of pathology.

[191]  D. Strickland,et al.  The Very Low Density Lipoprotein Receptor Mediates the Cellular Catabolism of Lipoprotein Lipase and Urokinase-Plasminogen Activator Inhibitor Type I Complexes (*) , 1995, The Journal of Biological Chemistry.

[192]  L. Crofford,et al.  Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin‐1: a potential mechanism for inflammatory angiogenesis , 1995, FEBS letters.

[193]  G. Gilliland,et al.  Heparin Binding by Fibronectin Module III-13 Involves Six Discontinuous Basic Residues Brought Together to Form a Cationic Cradle (*) , 1995, The Journal of Biological Chemistry.

[194]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[195]  G. Haines,et al.  Adhesion molecule expression in human synovial tissue. , 1993, Arthritis and rheumatism.

[196]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.

[197]  K. Miyazono,et al.  Platelet‐derived endothelial cell growth factor , 1991, Journal of cellular biochemistry.

[198]  K. Brandt,et al.  Synovial inflammation in patients with early osteoarthritis of the knee. , 1990, The Journal of rheumatology.

[199]  B. Bresnihan,et al.  Analysis of the histologic variation of synovitis in rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[200]  E. Crivellato,et al.  Mast cells in rheumatoid arthritis , 1984, Clinical Rheumatology.

[201]  G. Bray.  Overweight Is Risking Fate , 1984, The Western journal of medicine.

[202]  C. Malemud.  Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[203]  S. Wadler.  Targeted therapy in colorectal cancer. , 2007, Clinical colorectal cancer.

[204]  N. Dhalla,et al.  Angiogenesis--a new target for future therapy. , 2006, Vascular pharmacology.

[205]  H. Lebovitz.  Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[206]  G. Semenza,et al.  Regulation of gene expression by HIF-1. , 2006, Novartis Foundation symposium.

[207]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[208]  C. Brinckerhoff,et al.  Matrix metalloproteinases: role in arthritis. , 2006, Frontiers in bioscience : a journal and virtual library.

[209]  C. Costa.  Essential Role of Angiogenic Factors and Bone Marrow-Derived Endothelial/Hematopoietic Cells in the Growth of Solid Tumors , 2006 .

[210]  D. Walsh,et al.  Osteoarthritis, angiogenesis and inflammation. , 2005, Rheumatology.

[211]  D. Creamer,et al.  Angiogenesis in psoriasis , 2004, Angiogenesis.

[212]  J. Steinmeyer.  Cytokines in osteoarthritis-current status on the pharmacological intervention. , 2004, Frontiers in bioscience : a journal and virtual library.

[213]  E. Paleolog,et al.  Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies , 2004, Springer Seminars in Immunopathology.

[214]  M. Slevin,et al.  Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing in diabetes , 2004, Angiogenesis.

[215]  S. Gately.  The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.

[216]  L. Aiello,et al.  Angiogenesis and ophthalmic disease , 2004, Angiogenesis.

[217]  J. Russo,et al.  17β-Estradiol-Mediated Vessel Assembly and Stabilization in Tumor Angiogenesis Requires TGFβ and EGFR Crosstalk , 2004, Angiogenesis.

[218]  M. Héroult,et al.  Inflammatory triggers of lymphangiogenesis. , 2003, Lymphatic research and biology.

[219]  P. Brooks.  Inflammation as an important feature of osteoarthritis. , 2003, Bulletin of the World Health Organization.

[220]  Judy H. Cho,et al.  Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. , 2003, Gastroenterology.

[221]  H. Uramoto,et al.  Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor. , 2003, Acta biochimica Polonica.

[222]  K. Ley.  Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants , 2001, Immunologic research.

[223]  M. Lingen,et al.  Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. , 2001, Archives of pathology & laboratory medicine.

[224]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[225]  T. Kreis,et al.  Guidebook to the extracellular matrix, anchor, and adhesion proteins , 1999 .

[226]  S. Goodman,et al.  Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist , 1999 .

[227]  J. Parsonnet.  Microbes and malignancy : infection as a cause of human cancers , 1999 .

[228]  K. Tanikawa,et al.  Vascular endothelial growth factor in patients with rheumatoid arthritis. , 1998, Scandinavian journal of rheumatology.

[229]  M. Feldmann,et al.  Reduced synovial vascularity following TNF alpha blockade in rheumatoid arthritis. , 1998 .

[230]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[231]  E. Braunwald.  Harrison's Principles of Internal Medicine , 1950 .

[232]  Identification and characterization of a very low density lipoprotein receptor–binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity , 2022 .

[233]  E. Acosta,et al.  Journal of Autoimmune Diseases Autoantigenic Nuclear Proteins of a Clinically Atypical Renal Vasculitis , 2022 .